Roche (RHHBY) expects an increase in Group sales in the mid single digit range CER for 2026. Core earnings per share are targeted to develop in the high single digit range CER. Roche expects to further increase its dividend in Swiss francs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech’s treatment of KRAS G12C-positive NSCLC granted FDA orphan designation
- Genetech says Phase III METEROID study of Enspryng meets primary endpoint
- Roche announces U.S. FDA accepted sBLA for Gazyva/Gazyvaro
- Roche’s Genentech reports FDA approval of sBLA for Gazyva
- Trump names Erica Schwartz CDC Director